Company: BOLT
Filing Date: 2025-05-28
Form Type: 8-K
Source: 0000950170-25-077880
Chunk: 0

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-05-28
Form: 8-K
Item: Item 5.07
Chunk 0
---
Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 27, 2025, Bolt Biotherapeutics, Inc. (the “ Company”) held its 2025 annual meeting of stockholders (the “ Annual Meeting”) to consider and vote on the three proposals set forth below, each of which is described in greater detail in the Company’s definitive proxy statement on Schedule 14A filed with the U. S. Securities and Exchange Commission on April 25, 2025. A total of 38,339,697 shares of the Company's common stock were entitled to vote as of April 15, 2025, the record date for the Annual Meeting, of which 24,362,318 shares were represented in person or by proxy at the Annual Meeting. Proxies for the Annual Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition of management’s solicitation.

a.

The following director nominees were elected to serve as Class I members of the Company’s board of directors until the Company’s 2028 Annual Meeting of Stockholders, or until their respective successor is duly elected and qualified, or until their respective death, resignation or removal:

  Nominee                Votes For                      Votes Withheld                   Broker Non-Votes                  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Laura Berner                          10,565,170                          908,222                            12,888,926  
  Brian O'Callaghan                     11,214,137                          259,255                            12,888,926  

b.

The selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified.

  Votes For                      Votes Against                   Votes Abstaining               
 ────────────────────────────────────────────────────────────────────────────────────────────────
                 23,330,316                         931,665                            100,337  

c.

The approval of an amendment to the certificate of incorporation to effect a reverse stock split of the Company's issued and outstanding common stock was approved.

  Votes For                      Votes Against                     Votes Abstaining               
 ──────────────────────────────────────────────────────────────────────────────────────────────────
                 20,983,236                         3,224,611                            154,471  

SIGNATURES